GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Genscript Biotech 1548.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

31.32

+3.09%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in USD, from our data supplier.

FY2025

Revenue

$959.5m

FY2016FY2025

Net income

−$532.8m

FY2016FY2025

Free cash flow

$241.7m

FY2016FY2025

Shareholders' equity

$3.96bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue$959.5m$75.8m$71.5m$79.8m$511.1m$390.8m$273.4m$231.0m$152.6m$114.7m
Research and development$71.2m$6.9m$6.7m$49.7m$358.4m$263.4m$186.0m$74.1m$18.1m$9.5m
Operating income$255.2m$1.2m$3.3m−$55.9m−$494.0m−$204.5m−$131.3m$5.1m$39.6m$24.9m
Net income−$532.8m$377.6m−$12.2m−$28.9m−$347.9m−$204.9m−$96.9m$21.2m$26.1m$26.2m
Diluted earnings per share-0.240.17-0.01-0.01-0.17-0.10-0.050.010.020.02

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assets$4.85bn$5.28bn$3.39bn$2.55bn$2.23bn$1.45bn$889.4m$917.0m$504.3m$226.0m
Cash and short-term investments$843.0m$621.2m$1.93bn$1.46bn$1.41bn$771.2m$426.5m$564.6m$126.9m$136.5m
Total liabilities$876.3m$954.9m$1.34bn$1.18bn$846.2m$631.8m$517.1m$423.7m$275.9m$42.0m
Debt$258.8m$723.7m$417.0m$349.8m$156.4m$52.4m$22.4m$10.5m——
Shareholders' equity$3.96bn$4.32bn$1.39bn$1.01bn$1.05bn$901.7m$382.8m$478.7m$217.8m$177.6m
Shares outstanding2,228m2,178m2,112m2,103m2,085m1,953m1,878m1,857m1,726m1,724m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations$325.5m$9.6m−$286.9m−$120.3m−$136.8m−$151.1m−$30.0m$307.7m$21.4m$33.3m
Capital spending−$83.8m−$18.9m−$157.7m−$216.1m−$133.0m−$121.9m−$110.4m−$70.8m−$29.2m−$8.6m
Free cash flow$241.7m−$9.2m−$444.6m−$336.4m−$269.8m−$273.0m−$140.3m$236.8m−$7.8m$24.7m
Dividends paid————————−$2.6m−$2.6m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022
Revenue$403.2m$440.8m$518.8m$39.4m$36.4m$57.1m$391.3m$316.1m
Operating income$49.4m$76.2m$179.1m$42,201$1.1m−$24.6m−$222.6m−$260.7m
Net income−$129.0m−$507.4m−$25.5m$400.0m−$22.3m−$241,733−$93.6m−$91.3m
Diluted earnings per share-0.06-0.23-0.010.18-0.01-0.00-0.04-0.04
Cash from operations—$92.0m$232.0m$9.0m$10.0m−$99.0m−$187.0m−$58.0m
Capital spending—−$51.0m−$32.0m−$18.0m−$17.0m−$172.0m−$80.0m−$142.0m
Free cash flow—$41.0m$200.0m−$9.0m−$7.0m−$271.0m−$267.0m−$200.0m
Total assets$4.79bn$4.85bn$5.43bn$5.28bn$3.33bn$431.9m$3.38bn$324.7m
Cash and short-term investments$831.2m$843.0m$938.4m$621.2m$1.87bn$245.8m$2.14bn$186.6m
Debt$203.2m$532.3m$218.6m$170.6m$350.5m$53.2m$380.9m$44.6m
Shareholders' equity$3.88bn$3.96bn$4.42bn$4.32bn$1.21bn$177.4m$1.35bn$128.8m

Financial ratios

Data as of 22 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020
Operating margin26.6%1.6%4.7%-70.0%-96.7%-52.3%
Net margin-55.5%498.2%-17.0%-36.3%-68.1%-52.4%
Return on equity-13.5%68.5%-6.9%-22.4%-33.3%-22.7%
Return on assets-11.0%56.1%-2.8%-8.9%-15.6%-14.2%
Free cash flow yield0.6%0.3%-0.2%0.1%-0.0%-0.0%
Revenue growth61.4%6.1%-10.4%22.4%30.8%43.0%
Earnings growth-118.0%-3202.2%-57.9%-34.8%69.7%111.5%
Current ratio1.47x2.72x4.76x3.23x3.97x3.03x
Debt to equity0.12x0.03x0.25x0.30x0.12x0.05x
Equity ratio81.6%81.9%41.1%39.7%46.8%62.3%
Interest coverage14.74x1.16x0.95x-33.01x-207.74x-144.25x
R&D as a share of sales7.4%9.0%9.4%62.3%70.1%67.4%
Buybacks as a share of market value-2.3%-3.1%-0.4%-0.9%-6.8%-4.0%

Growth per year

Compound annual rate

3 years5 years10 years
Revenue129.1%19.7%27.2%
Operating income——37.1%
Net income164.1%21.1%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin24.8%17.2%-23.7%-18.5%
Net margin-15.0%-16.5%-35.9%-25.6%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-6.67.3-439.5-230.5-26.4-13.7
Price to sales3.736.174.983.618.07.2

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 5 Jun 2017.

FY2017
Paid in the year0.012

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.